Since colorectal cancer is a significant contributor to the expression of PD-L1, IFNγ, and miR-93-5p, by comprehending the mechanisms that drive PD-L1 expression within the tumor, new prospects may emerge for focused immunotherapy in the treatment of CRC (p values < 0.05) [121]. This evidence concerns the gene IFNG and neoplasm.